Search academic texts

Information × Registration Number 0222U004974, 0121U100263 , R & D reports Title 617.Comorbide conditions in patients with the metabolic syndrome: familial hypercholesterolemia, fatty hepatosis, periodontopathy (parthenogenesis, diagnosis, correction). popup.stage_title Head Poliakov Anatolii Ye., д.мед.н. Registration Date 01-12-2022 Organization Odessa National Medical University popup.description2   86 patients with metabolic syngrome and comorbid nonalcoholic fatty liver disease were carried ouy general clinical and laboratory-instrumental examinations. The patients were divided into 2 groups: 41 patients with the use of rosuvastatin were added quercetin 40 mg 3 times a day for 3 months to the basic therapy (group 1). The basic therapy with rosuvastation only was carried out in 45 patients (group 2). After the treatment on the 90 th day, positive changes in lipid metabolism were registered in all the patients. In patients of the group 1 the level of low-density lipoproteins decreased by 39,5%, the triglycerides – twice, activity of transaminase – by 30,0%. The high – density lipoproteins level increased by 72,0%. Interleukins and cytokeratin -18 concentration reliable decreased by 23,0%. It was found that the comorbid course of nonalcoholic fatty liver disease is accompanied by an increase in the oxidative stress intensity, which is determined by increased level in the blood of the end products of lipid peroxidation – malondialdehyde – on average 3,8 times. The use of quercetin in the complex therapy of the nonalcoholic fatty liver disease contributes to a reliable reduction in the oxidative stress intensity, an increase in the antioxidant protection activity (superoxide dismutase), the consequence of which is a significant reduction in the hepatocytes apoptosis process (decrease in cytokeratine-18 level 1,27 times as much). Product Description popup.authors Muravska Olena M. Polyakov Anatoliy Ye Prokopova Tatyana M. Tretyachenko Yuriy V. popup.nrat_date 2022-12-01 Close